Table 1. Echocardiographic measurements in 5 groups of rats 4 weeks after gene transfer.
| Groups | Control | Mock | Ad-EGFP | Ad-ACE2 | Cilazapril |
|---|---|---|---|---|---|
| HR (bpm) | 366.78 ± 12.93 | 372.38 ± 20.72 | 362.19 ± 18.02 | 377.53 ± 11.28 | 356.28 ± 17.28 |
| sBP (mmHg) | 124.73 ± 6.24 | 80.26 ± 3.27# | 77.28 ± 4.83# | 83.05 ± 5.50# | 84.37 ± 6.98# |
| dBP (mmHg) | 96.08 ± 5.32 | 62.83 ± 3.37# | 57.37 ± 2.94# | 65.27 ± 4.21# | 63.89 ± 3.19# |
| LVEF (%) | 72.34 ± 0.84 | 38.86 ± 2.22* | 35.81 ± 2.24* | 60.64 ± 0.79 | 50.5 ± 1.65& |
| ES (%) | 42.31 ± 0.49 | 19.48 ± 1.38* | 17.77 ± 1.24* | 36.24 ± 0.44 | 28.61 ± 1.25& |
| LVESD (mm) | 3.12 ± 0.27 | 5.52 ± 0.16* | 5.68 ± 0.57* | 4.11 ± 0.07 | 4.24 ± 0.17 |
| LVEDD (mm) | 4.90 ± 0.51 | 7.53 ± 0.26* | 7.66 ± 0.19* | 6.08 ± 0.36 | 6.79 ± 0.26& |
HR, heart rates; sBP, systolic blood pressure; dBP, diastolic blood pressure. LVEF, left ventricular ejection fraction; ES, left ventricular fractional shortening; LVESD, left ventricular end-systolic diameter; LVEDD, left ventricular end-diastolic diameter. N is 8–15 in each group. Data were expressed by mean ± s.e.m. #P < 0.05 vs. Control; *P < 0.05 vs. Control, Ad-ACE2 and Cilazapril; &P < 0.05 vs. Ad-ACE2.